Duke logo

AHEP1531: Hepatoblastoma in Children & Young Adults - Clinical Trial

What is the Purpose of this Study?

We are doing this study to compare the effects (good and/or bad) of cisplatin with the combination of chemotherapy in treating children and young adults with hepatoblastoma or liver cancer after surgery.

What is the Condition Being Studied?

Children and young adults with Hepatoblastoma

Who Can Participate in the Study?

Adults and children who:
- Are up to age 30
- Have a newly diagnosed primary pediatric hepatic malignancy

Age Group
Adults, Children

What is Involved?

If you choose to join this study, you will:
- Get treatments based on the group you are assigned

-- Group A: patients with very low risk disease
-- Group B: patients with low risk disease
-- Group C: patients with intermediate risk disease
-- Group D: patients with high risk disease

Depending on your assigned group, you may:
-- Get chemotherapy drugs such as cisplatin, doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine and/or oxaliplatin.
--- Be randomized (like flipping a coin) to different types or doses of chemotherapy
-- Have surgery to remove your tumor

Study Details

Full Title
AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Principal Investigator
Pediatric Hematology-Oncology Specialist
Protocol Number
IRB:PRO00101163
NCT:NCT03533582
Phase
Phase II/III
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
studyrecruitment@duke.edu
or
919-681-5698